Saturday | Courier Times News
Drug firm guilty in 'off-label' scheme
A pharmaceutical company pleaded guilty in federal court Friday to promoting drugs for unintended purposes and has agreed to pay $50 million in criminal penalties and $375 million in civil penalties.
State Receives Settlement in National Medicaid Fraud
Attorney General Anne Milgram announced today that New Jersey will receive nearly $2.5 million in restitution in a national Medicaid fraud settlement with pharmaceutical company Cephalon Inc.
There is such a thing as too much of a good thing. Eli Lilly said yesterday that it "resolved an investigation" by 32 states and the District of Columbia over allegations that it marketed its antipsychotic, ...
Biotech 2008 to Feature Cephalon CEO, Frank Baldino, Jr., Ph.D. as Luncheon Keynote Speaker
Collaborate. Innovate, the eighth annual joint symposium of BioNJ and Pennsylvania Bio, will feature Frank Baldino, Jr., Ph.D., chairman and CEO of Cephalon, Inc.
Phila.-area stocks mauled by market fears
The Dow Jones industrial average was down an alarming 5 percent Monday morning despite Friday's passage of the bank bailout.
Drugmaker Cephalon Completes $443.9M Settlement With DOJ, States...
Main Category: Pharma Industry / Biotech Industry Also Included In: Health Insurance / Medical Insurance Cephalon on Monday completed a $443.9 million settlement with federal and state regulators related to ...
Pharma Update: A Victory for Amgen, A Gift from Congress, and More
Amgen wins patent case against Roche - The courts have decided that Roche cana TMt sell its anemia drug Mircera in the United States, since it violates patent law by competing with Amgen a TMs anemia offerings, ...
Vt. Medicaid to receive $1.1 million in drug case
The Vermont Attorney General's office says the state's Medicaid program will receive almost $1.1 million to settle charges the pharmaceutical company Cephalon, Inc., improperly marketed certain drugs.
South Dakota gets $49,000 in drug settlement
SDDrug Settlement,0101 South Dakota gets $49,000 in drug settlement Eds: APNewsNow.
What's a life worth to Cephalon and its stockholders?
Apparently, not very much, considering their off-label promotions of opiate-laced lollipops.
Aloha Petroleum Ltd. , a privately held oil marketer, has selected CBX , a consultancy agency based in New York, to design a prototypical convenience store, beginning with a new, ground-up unit to open on Oahu ...
Cephalon Concludes All Outstanding Federal and State Government...
Cephalon, Inc. announced today it has finalized a previously announced agreement in principle with the U.S. Attorney's Office for the Eastern District of Pennsylvania, the U.S. Department of Justice and various ...
EPA fines company over pesticides
The U.S. Environmental Protection Agency has levied a $65,050 fine against Vector Tobacco Inc.
Nevada settles with drug maker Cephalon for $6.9 million
Mon, Sep 29, 2008 Nevada Attorney General Catherine Cortez Masto announced today that the state had reached a tentative $6.9 million agreement with a major drug manufacturer.
Cephalon To Pay $425M For Improper Drug Marketing
Drug maker Cephalon, completing a previously announced settlement, will pay $425 million for illegally marketing a highly addictive lollipop painkiller and two other drugs for non-approved uses.
Biocon ranked seventh top biotech employer globally
Bangalore-based Biocon Ltd has been ranked as the 7th largest employer amongst the top global biotechnology companies, behind Biogen but ahead of global life science companies Gilead , Cephalon and Amylin.
Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism
The FDA delivered to Cephalon a letter yesterday saying it would not approve expanded indications for its pain drug Fentora until the company gave it more information on how it would prevent the drug from being ...
Mark S. Purcell joined Nason Construction as business development manager and project executive.
As fundamentals-focused long-term investors, Fools never base an investment decision on the daily gyrations of the market.
For drug developers, few events can affect their share price more than an FDA decision about one of their drug candidates.